accuracy of chads2, cha2ds2- vasc and has-bled scores in evaluation of stroke and bleeding risk...
TRANSCRIPT
Accuracy of CHADS2, CHA2DS2-VASC and HAS-BLED scores in
evaluation of stroke and bleeding risk
First author: Alexandra Murar
Co-author: Andreia Gherasâm
Coordinators: Dr. Monica Dorgo, Prof.Dr. Emilian Carașca
Marisiensis 2014
Introduction
Marisiensis 2014
Atrial fibrillation
Bleeding risk
OACIschaemic
stroke
Age
Hypertension pressure
Cerebrovascular disease
Renal failure
Marisiensis 2014
Materials and methods
It was performed a retrospective, observational study on 146 patients from the medicine and cardiology departments in our hospital, with a follow up period of 6 months. Data were obtained from medical and computerized records, which were later entered into a statistical analysis software.
From 146 patients 69 were men and 77 women with an average age of 69, regardless of the origin of the demographic and ethnic characteristics. Present comorbidities were hypertension, diabetes, history of stroke, heart failure.
We considered patients with atrial fibrillation of which 131 (89,72%) were on anticoagulants and 15 (10,27%) were not anticoagulated, after which we calculated the CHADS2, CHA2DS2-Vasc and HAS-BLED scores. We divided the stroke risk categories calculated through CHADS2 and CHA2DS2–Vasc scores in low, medium and high. A HAS-BLED score >3, a CHA2DS-Vasc ≥2 ,and CHADS2 >2 were considered high.
Patients were divided into two groups: Group A with oral anticoagulant therapy Group B with non-anticoagulant medication
Marisiensis 2014
Classification according to European Society of Cardiology (ESC) 2010
First diagnosed episode of atrial fibrillation
Paroxymal(usualy≤ 48 h)
Persistent(>7 days or
requires CV)
Long-standing Persistent (>1
year)
Permanent(accepted)
Marisiensis 2014
In clinical practice
FiA Characteristics
ParoxysmalSelf-limited recurrent episodes lasting under 7 days
PersistentRecurrent episodes lasting more than 7 days to a month
PermanentLong episode, it was decided by mutual agreement of the doctor / patient on incidence control (unable to restore sinus rhythm)
Marisiensis 2014
CHA2DS2-Vasc - Risk factors for stroke and thrombo-embolism
“ major” risk factors
• Previous stroke, TIA, or systemic embolism - 2 points
• Age > 75 years - 2 points !!!
“ non-major” risk factors
• Heart failure or moderate /severe LV systolic dysfunction (e.g. LV EF < 40%)
• Hypertension • Diabetes mellitus
• Female sex – 1 point• Age 65–74 years - 1 point • Vascular disease
Marisiensis 2014
HAS-BLED bleeding risk score
• H- Hypertension 1
• A - Abnormal renal and liver function (1 point each) 1 or 2
• S -Stroke 1
• B - Bleeding 1
• L - Labile INRs 1
• E - Elderly (e.g. age >65 years) 1
• D -Drugs or alcohol (1 point each) 1 or 2
• Maximum 9 points
‘Hypertension’is defined as systolic blood pressure >160 mmHg. ‘Abnormal kidney function’is defined as the presence of chronic dialysis or renal transplantation or serum creatinine ≥200mmol/L. ‘Abnormal liver function’ is defined as chronic hepatic disease (e.g. cirrhosis) or biochemical evidence of significant hepatic derangement (e.g. bilirubin.2 x upper limit of normal, in association with aspartate aminotransferase/alanine aminotransferase/alkaline phosphatase 3 x upper limit normal, etc.). ‘Bleeding’ refers to previous bleeding history and/or predisposition to bleeding, e.g. bleeding diathesis, anaemia, etc. ‘Labile INRs’ refers to unstable/high INRs or poor time in therapeutic range (e.g. <60%). ‘Drugs/alcohol’ use refers to concomitant use of drugs, such as antiplatelet agents, non-steroidal anti-inflammatory drugs, or alcohol abuse, etc.
Marisiensis 2014
Inclusion and exclusion criteria
Study inclusion criteria were:
• paroxysmal, persistent either permanent atrial fibrillation
regardless of its etiology, at least one electrocardiographic confirmation
•effective anticoagulation (INR between 2 and 3)
Exclusion criteria of the study were:
•patients with valvular diseases•atrial fibrillation secondary hyperthyroidism, acute pericarditis myocarditis, pulmonary disease or after cardiovascular surgery •pregnant patients•patients whose observation form were not completed•patients who refused any kind of treatment
Marisiensis 2014
Results
Statistical analysis of data was performed using the computer program GraphPad Prism 6. t-test and ANOVA were used, the confidence limits was 95% and the statistical estimation of the results was performed according to the decision criteria of statistical tests: • p ≥ 0.05 - insignificant differences • p <0.05 - significant differences • p <0.01 – very significant differences • p <0.001 - highly significant differences Subject touched in this study aims to assess the risk of stroke in patients in group A based on CHADS2 scores and CHA2DS2-Vasc also the hemorrhagic strokes frequency based on HAS-BLED score
Marisiensis 2014
Statistical correlation
Confidence interval 95%
P value < 0.0001Significantly different? (P < 0.05)
yes
Marisiensis 2014
Confidence interval 95%
P value < 0.0001
Significantly different? (P < 0.05)
yes
Marisiensis 2014
Confidence interval 95%
P value < 0.0001
Significantly different? (P < 0.05)
yes
Marisiensis 2014
Marisiensis 2014
P value < 0,0001
Conclusions
Patients with AF and a high HAS-BLED score develop a higher clinical benefit from OAC when balancing ischaemic stroke against intracranial bleeding. HAS-BLED score was superior to CHADS2-Vasc in predicting bleeding events which is concordant with the speciality literature. Comparing stroke risk groups using CHADS2 and CHA2DS2-Vasc tools, showed a higher rate of cardioembolic events in medium risk group whilst in CHA2DS2-Vasc group, the rate of stroke was superior in the high risk group.
Marisiensis 2014
References
• Camm AJ, Kirchhof P, Lip GY, Schotten U, et al ; Guidelines for the management of atrial fibrillation: the Task Force for the Man-agement of Atrial Fibrillation of the European Society of Cardiology (ESC).Euro-pace2010;12:1360 – 1420.
• Roldan V, Marin F, Manzano-Fernandez S, Gallego P, Vilchez JA, Valdes M, Vicente V, Lip Gy; The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation;2013;10;62(23):2199-204. [Pubmed: 24055744]
• Lighezan, Roxana Buzaş;Atrial fibrillation; Assessing the risk of systemic embolism and bleeding ;Romanian Journal of Cardiology; 23;Supplement A; 2013.
• L. Gherasim , D. Vinereanu; New oral anticoagulants in the treatment of non-valvular atrial fibrillation; Romanian Journal of Cardiology; 23;Supplement A; 2013.
• E. Apetrei; Atrial fibrillation. Epidemiology. Diagnosis; Romanian Journal of Cardiology; 23;Supplement A; 2013.
Marisiensis 2014
• Singth M, Adigopula S, Patel P, Kiran K. Recent advances in Oral Anticoagulation for Atrial Fibrillation. The Adv Cardiovas Dis 2010; 4(6):395-407.
• European Heart Rhythm Association et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart. J. 2010; 31:2369–2429.
• Management of atrial fibrillation. [bmj.b5216]
Marisiensis 2014